Современные представления о сочетании бронхиальной астмы и хронической обструктивной болезни легких
- Авторы: Трушина Е.Ю.1, Костина Е.М.1, Типикин В.А.1, Орлова Е.А.1
-
Учреждения:
- Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава России
- Выпуск: Том 30, № 14 (2023)
- Страницы: 106-110
- Раздел: Пульмонология/ЛОР/ОРВИ
- URL: https://journals.eco-vector.com/2073-4034/article/view/626256
- DOI: https://doi.org/10.18565/pharmateca.2023.14.106-110
- ID: 626256
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Термин «перекрест бронхиальной астмы (БА) и хронической обструктивной болезни легких» (ХОБЛ; asthma-chronic obstructive pulmonary disease overlap – ACO) – это гетерогенное состояние, при котором наблюдается ограничение потока воздуха, которое не является полностью обратимым, а также имеет клинические и воспалительные признаки как БА астмы, так и ХОБЛ. Цель исследования – анализ материала по данной теме. Был использован аналитический метод изучения диагностики, клинических проявлений и подходов к терапии пациентов с сочетанием БА и ХОБЛ за последние 10 лет (2013–2023) по базам: PubMed, Wiley, EMBASE database, Cochrane Library.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Елена Юрьевна Трушина
Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава России
Автор, ответственный за переписку.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN-код: 2164-6580
кандидат медицинских наук, доцент кафедры пульмонологии и фтизиатрии
Россия, ПензаЕ. М. Костина
Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава России
Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
SPIN-код: 2111-8827
Россия, Пенза
В. А. Типикин
Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава России
Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
SPIN-код: 7403-8592
Россия, Пенза
Е. А. Орлова
Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО РМАНПО Минздрава России
Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1402-2940
SPIN-код: 1700-4848
Россия, Пенза
Список литературы
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. doi: 10.1016/S0140-6736(17)32154-2.
- Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67:165–71. doi: 10.1016/j.alit.2018.02.002.
- Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) 2015. Accessed June 18, 2023. URL: https://ginasthma.org/wp-content/uploads/2016/01/ACOS_2015.pdf
- Fingleton J., Hardy J., Beasley R. Treatable traits of chronic airways disease. Curr Opin Pulm Med. 2018;24(1):24–31 doi: 10.1097/MCP.0000000000000445.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. Accessed June 16, 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2023. Accessed June 02, 2023.
- Bourdin A., Suehs C.M., Marin G., et al. Asthma, COPD, and overlap in a national cohort: ACO on a gradient. J Allergy Clin Immunol. 2018;141:1516–18. doi: 10.1016/j.jaci.2017.11.049.
- Cataldo D., Corhay J.L., Derom E., et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–13. doi: 10.2147/COPD.S124459.
- Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26 doi: 10.1016/S2213-2600(18)30006-7.
- Tong X., Wang D., Liu S., et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–18. doi: 10.2147/COPD.S152655
- Liu L., Zhang X., Liu Y., et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respir Res. 2019;20:95. Doi: 10.1186 / s12931-019-1051-912. Shirai T., Hirai K., Gon Y., et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol. 2019;7:134–45. Doi: 10.1016 / j.jaip.2018.06.015
- Katoh S., Ikeda M., Shirai R., et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018;55:1052–58. doi: 10.1080/02770903.2017.1391281.
- Gon Y., Maruoka S., Ito R., et al. Utility of serum YKL-40 levels for identification of patients with asthma and COPD. Allergology International. 2017;66:624–26. Doi: 10.1016 / j.alit.2017.02.010.
- Jo Y.S., Kwon S.O., Kim J., et al. Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap. J Thorac Dis. 2018;10:5047–56. Doi: 10.21037 / jtd.2018.07.86.
- Rendell H.K., Vestibo J., Agusti A., et al. Heterogeneity within and between asthma and/or COPD diagnosed by a doctor: A NEW cohort. Int J Chron Obstruct Pulmon Dis. 2021;58:2003927. doi: 10.1183/13993003.03927-2020.
- Leung J.M., Sin D.D. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. Br Med J. 2017;358:j3772. Doi: 10.1136 /bmj.j3772.
- Hikichi M., Hashimoto S., Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67:179–86. doi: 10.1016/j.alit.2018.01.001.
- Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis. J Allergy Clin Immunol. 2015;136:521–29. doi: 10.1016/j.jaci.2015.06.018.
- Sahu A., Swaroop S., Kant S., et al. Signatures for chronic obstructive pulmonary disease (COPD) and asthma: A comparative genetic analysis. J Biomed Sci. 2021;78:177–83. doi: 10.1080/09674845.2021.1905988.
- Hobbs B.D., de Jong K., Lamontagne M., et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017;49:426–32. Doi: 10.1038/ ng.3752.
- Christenson S.A., Steiling K., van den Berge M., et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191:758–66 doi: 10.1164/rccm.201408-1458OC.
- Padrаo Е., Araujo D., Todo Bom A., et al. Asthma-COPD overlap: A Portuguese survey. Pulmonology. 2018;24(3):173–81. doi: 10.1016/j.rppnen.2017.11.009.
- Lim H.S., Choi S.M., Lee J., et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–57. Doi: 10.1016 / j.anai.2014.08.021.
- Lee S.Y., Park H.Y., Kim E.K., et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2797–803. doi: 10.2147/COPD.S114964.
- Su V.Y., Yang K.Y., Yang Y.H., et al. Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma. J Allergy Clin Immunol. 2018;6:1927–35. doi: 10.1016/j.jaip.2018.01.035.
- Hanania N.A., Chipps B.E., Griffin N.M., et al. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143:1629–33.e2. doi: 10.1016/j.jaci.2018.11.032.
- Kuprys-Lipinska I., Palczynski C., Molinska J., et al. Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. Postepy Dermatologii I Alergologii. 2019;36:239–41. doi: 10.5114/ada.2018.73140
- Pavord I.D., Chanez P., Criner G.J., et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377:1613–29. doi: 10.1056/NEJMoa1708208.
- Pavord I.D., Chapman K.R., Bafadhel M., et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–70. doi: 10.2147/COPD.S294333
- Criner G.J., Celli B.R., Brightling C.E., et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019;381:1023–34. doi: 10.1056/NEJMoa1905248.
Дополнительные файлы
![](/img/style/loading.gif)